Trial Profile
A study to evaluate the efficacy of exenatide-saroglitazar combination in treatment of non alcoholic fatty liver disease.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jul 2015
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Saroglitazar (Primary)
- Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 28 Jul 2015 New trial record
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.